Cargando…

Bortezomib-based vs non-bortezomib-based post-transplantation treatment in multiple myeloma patients: a systematic review and meta-analysis of Phase III randomized controlled trials

OBJECTIVE: To evaluate the efficacy and safety of bortezomib-based vs non-bortezomib-based post-transplantation therapy in patients with multiple myeloma. METHODS: Data of relevant randomized controlled trials assessing the effect of bortezomib as post-transplantation consolidation or maintenance th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xiaoping, He, Colin K, Meng, Xiangyu, He, Li, Li, Kaili, Liang, Qing, Shao, Liang, Liu, Shangqin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4474400/ https://www.ncbi.nlm.nih.gov/pubmed/26109870 http://dx.doi.org/10.2147/OTT.S84828

Ejemplares similares

Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations
por: Liu, Jianhao, et al.
Publicado: (2021)

Clinical outcomes of bortezomib-based therapy in myeloma
por: Djebbari, Faouzi, et al.
Publicado: (2018)

BAFF is involved in macrophage-induced bortezomib resistance in myeloma
por: Chen, Jing, et al.
Publicado: (2017)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

Caspase-8: Friend or Foe in Bortezomib/Lenalidomide-Based Therapy for Myeloma
por: Zhou, Liang
Publicado: (2022)

The Choice of Regimens Based on Bortezomib for Patients with Newly Diagnosed Multiple Myeloma
por: He, Jingsong, et al.
Publicado: (2014)

Bortezomib in Kidney Transplantation
por: Raghavan, Rajeev, et al.
Publicado: (2010)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen
por: Jacobus, S J, et al.
Publicado: (2016)

New bortezomib-based combination therapy for elimination of myeloma cells
por: Meister, S, et al.
Publicado: (2009)

Long-term outcomes of different bortezomib-based regimens in Chinese myeloma patients
por: Wang, Hua, et al.
Publicado: (2016)

Bortezomib Treatment Modulates Autophagy in Multiple Myeloma
por: Di Lernia, Giuseppe, et al.
Publicado: (2020)

Entinostat-Bortezomib Hybrids against Multiple Myeloma
por: Ferro, Angelica, et al.
Publicado: (2023)

Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
por: O’Connor-Byrne, N., et al.
Publicado: (2019)

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
por: Richard, Shambavi, et al.
Publicado: (2021)

β-catenin inhibitors ICG-001 and pyrvinium sensitize bortezomib-resistant multiple myeloma cells to bortezomib
por: Wu, Cuicui
Publicado: (2022)

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
por: Rosiñol, Laura, et al.
Publicado: (2023)

Bortezomib
por: Rajappa, Senthil
Publicado: (2010)

Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study
por: Hjorth, Martin, et al.
Publicado: (2012)

Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma
por: Iida, Shinsuke, et al.
Publicado: (2018)

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
por: Spencer, Andrew, et al.
Publicado: (2018)

Mechanisms underlying synergism between circularized tumor necrosis factor‐related apoptosis inducing ligand and bortezomib in bortezomib‐sensitive or ‐resistant myeloma cells
por: Leng, Yun, et al.
Publicado: (2022)

TRIM21 enhances bortezomib sensitivity in multiple myeloma by halting prosurvival autophagy
por: Chen, Jing, et al.
Publicado: (2023)

Comparing efficacy and survivals of initial treatments for elderly patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials
por: Liu, Xiaoping, et al.
Publicado: (2016)

Exosomal mRNAs and lncRNAs involved in multiple myeloma resistance to bortezomib
por: Tang, Ju‐xian, et al.
Publicado: (2021)

NEDD4L binds the proteasome and promotes autophagy and bortezomib sensitivity in multiple myeloma
por: Huang, Xi, et al.
Publicado: (2022)

Bortezomib: the evidence of its clinical impact in multiple myeloma
por: Lancaster, Simon
Publicado: (2006)

Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits
por: Petrucci, Maria Teresa, et al.
Publicado: (2014)

Bortezomib-induced painful neuropathy in patients with multiple myeloma
por: Bilińska, Małgorzata, et al.
Publicado: (2013)

Tumor lysis syndrome in multiple myeloma treated with bortezomib
por: Dhanraj, K. M., et al.
Publicado: (2014)

Update on the optimal use of bortezomib in the treatment of multiple myeloma
por: Mohan, Meera, et al.
Publicado: (2017)

A feline case of multiple myeloma treated with bortezomib
por: Tani, Hiroyuki, et al.
Publicado: (2022)

Bortezomib-Induced Reticular Eruption in Patient with Multiple Myeloma
por: Han, Joseph, et al.
Publicado: (2023)

Expression of GITR Enhances Multiple Myeloma Cell Sensitivity to Bortezomib
por: Zhao, Yinghao, et al.
Publicado: (2015)

Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis
por: Zhang, Shijia, et al.
Publicado: (2020)

PHLPP Sensitizes Multiple Myeloma Cells to Bortezomib Through Regulating LAMP2
por: Liu, Xiao, et al.
Publicado: (2020)

Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma
por: Lee, Se Ryeon, et al.
Publicado: (2010)

Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma
por: Sidiqi, M. Hasib, et al.
Publicado: (2018)

Protein Kinase D 1 Predicts Poor Treatment Response and Unfavorable Survival of Bortezomib-Based Treatment, and Its Knockdown Enhances Drug Sensitivity to Bortezomib in Multiple Myeloma
por: Li, Xuesong, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m6mge9c6boo07rmdr7moorjao1